EXHIBIT 10.13
Execution Copy
STOCK EXCHANGE AGREEMENT
Among
ORGANITECH LTD,
THE SHAREHOLDERS OF ORGANITECH LTD
INCUBATE THIS! INC.
And
SHARONE PERLSTEIN
October __, 2000
THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933 (THE "1933 ACT"), NOR REGISTERED UNDER ANY
STATE SECURITIES LAW, AND ARE "RESTRICTED SECURITIES" AS THAT TERM IS DEFINED IN
RULE 144 UNDER THE 1933 ACT. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD OR
OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE 1933 ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE 1933
ACT, THE AVAILABILITY OF WHICH IS TO BE ESTABLISHED TO THE SATISFACTION OF THE
COMPANY.
STOCK EXCHANGE AGREEMENT
THIS STOCK EXCHANGE AGREEMENT (the "Agreement") is made this ____ day of
October, 2000 by and among (i) Lior Hessel ("HESSEL"), Technion Entrepreneurial
Incubator Company Ltd. ("TEIC", and collectively with HESSEL, the "Founding
Organitech Shareholders"); (ii) D. G. Pizza Ltd. and Arie and Anat Heller (the
"Outside Organitech Shareholders", and, collectively with the Founding
Organitech Shareholders, the "Organitech Shareholders"); (iii) Organitech Ltd, a
company formed under the Israeli Companies law ("Organitech"); (iv) Incubate
This! Inc., a Colorado corporation ("Incubate") and (v) Sharone Perlstein
("Perlstein").
BACKGROUND
A. Organitech is engaged in the business research and development related
to automatic cultivation of agricultural products as described in Exhibit A
attached hereto (the "Business").
B. . The issued and outstanding share capital of Organitech consists of
97,143 Ordinary Shares, all of which are owned by the Organitech Shareholders
(the "Organitech Group Stock"), and 12,460 Preferred Shares, all of which are
owned by Incubate.
C. Incubate holds certain warrants (the "Incubate Warrants" allowing it to
purchase an aggregate amount of 53,602 shares of capital stock of Organitech.
D. Organitech is obligated to issue an aggregate amount of 8,500 shares to
its employees under certain employee stock options.
E. Incubate desires to acquire the Organitech Group Shares thereby becoming
the sole shareholder of Organitech.
F. Organitech Shareholders agree to transfer to Incubate th Organitech
Group Shares in exchange for no less than 62.5% of Incubate's issued and
outstanding shares (following such issuance) on a fully diluted basis.
NOW THEREFORE, in consideration of the premises and of the mutual promises,
covenants, representations and warranties made in this Agreement, the parties
hereto, intending to be legally bound, hereby agree as follows:
1. DEFINITIONS ARTICLE ARTICLE
The following terms, as used herein, shall have the following respective
meanings, unless the context otherwise require:
1.1. "Accounts Receivable" shall mean all of the accounts receivable and
notes receivable of Organitech or Incubate, as the case may be, created or
arising in respect of the sale of products or services.
1.2. "Affiliate" shall mean, as to any specified person, (a) any other
person controlling, controlled by or under common control with such specified
person, (b) any officer, director or partner of such specified person, (c) any
other person of which such specified person is an officer, employee, agent,
director,
shareholder or partner or (d) any member of the Family Group of such specified
person or of any individual who is an Affiliate of such specified person by
reason of clause (a) or (b) of this definition. The term "control," with respect
to any person, means possession, direct or indirect, of the power to direct or
cause the direction of the management and policies of such person, whether
through the ownership of voting securities or a partnership interest, by
contract or otherwise. "Family Group" means, as to any individual, such
individual's spouse, ancestors, lineal descendants and trusts for the benefit of
any of the foregoing, provided that all the income beneficiaries and
remainderman of any such trust are such individual's spouse, ancestors or lineal
descendants.
1.3. "Books and Records" shall mean all records, documents, lists and
files, relating to the business of the relevant entity, including, without
limitation, executed originals of all contracts, purchase orders, sales orders,
, lists of accounts, customers, suppliers and personnel, shipping records, ,
historical sales data and all books, , files and business records.
1.4. "Business" shall have the meaning assigned to it in paragraph "A" of
this section; Background of this Agreement.
1.5. "Cash" shall mean all of the cash and cash equivalents of the relevant
entity.
1.6. "Closing" shall mean the consummation of the transactions contemplated
to occur hereunder pursuant to Section 3 hereof.
1.7. "Closing Date" shall mean November 10, 2000 or such (i) later date
requested by Organitech in good faith as reasonably necessary to allow
Organitech to complete its due diligence, or (ii) other date as shall be
mutually agreed to in writing by Sharon, Incubate, Organitech and the Organitech
Shareholders.
1.8. "Code" shall mean the Internal Revenue Code of 1986, as amended.
1.9. "Condition" shall mean the assets, liabilities, business, prospects,
operations, results of operations or condition (financial or otherwise) of the
relevant entity.
1.10. "Consents" shall mean any consent, waiver, approval, authorization,
certification or exemption required from any person or under any Contract or
requirement of law, as applicable.
1.11. "Contracts" shall mean any written or oral agreements, contracts,
commitments, leases and other instruments, documents and undertakings.
1.12. "Due Diligence Investigation" shall mean the Incubate Due Diligence
and the Organitech Due Diligence, as the case may be, as defined in Sections 6.1
and 6.2 hereof, respectively.
1.13. "Employees" shall mean each of the employees of the relevant entity.
1.14. "Exchange Act" shall mean the Securities Exchange Act of 1934, as
amended, and the rules and regulations thereunder.
1.15. "GAAP" shall mean generally accepted accounting principles in the
United States, applied on a basis consistent with preceding periods and
consistent throughout the periods involved.
1.16. "Governmental Entity" shall mean any federal, state or local
governmental authority, or any domestic or foreign administrative agency,
department, commission, board, bureau or other governmental authority or
instrumentality.
1.17. "Incubate Exchange Shares" shall have the meaning assigned to it in
Section 2.1 hereof.
1.18. "Incubate Financial Statements" shall have the meaning assigned to it
in Section 5.8.
1.19. "Incubate Public Shareholders" shall have the meaning assigned to it
in Section 3.2.2.7.
1.20. "Incubate Warrants" shall have the meaning assigned to it in
Background section above.
1.21. "Indemnifiable Losses" shall mean all Losses and Legal Expenses with
respect to which a party is required to indemnify the other in accordance with
Section 9.1.
1.22. "Indemnified Party" shall have the meaning assigned to it in Section
9.2 hereof.
1.23. "Indemnifying Party" shall have the meaning assigned to it in Section
9.2 hereof.
1.24. "Intellectual Property and Information" shall mean all the following
used in the Business: patents, applications for patents, trademarks, trademark
registrations, applications for trademark registrations, trade names, service
marks, copyrights, computer software and applications, trade secrets, product
related artwork and know- how, (including any registrations and applications for
registration thereof).
1.25. "Legal Expenses" shall mean any and all reasonable attorneys' fees
and out-of-pocket expenses and costs of any kind incurred by such person and its
counsel in any legal proceeding (whether as plaintiff or as defendant),
including, without limitation, investigating, preparing for, defending against
or providing evidence, producing documents or taking other action with respect
to any threatened or asserted claim.
1.26. "Liabilities" shall mean any and all obligations or liabilities of
any nature whatsoever, express or implied, matured or unmatured, disputed,
liquidated, unliquidated, absolute, fixed or contingent, known or unknown
(except as otherwise expressly set forth herein).
1.27. "Liens" shall mean liens, pledges, claims, charges, security
interests, and other encumbrances or rights of third parties of any nature
whatsoever.
1.28. "Losses" shall mean any and all damages, losses, obligations,
deficiencies, Liabilities, claims, encumbrances, penalties, fines, costs and
expenses, including, without limitation, any diminution in value of any real or
personal property and Legal Expenses.
1.29. "Original Date" shall mean the earliest date on which Perlstein
became a shareholder, officer or director of Incubate.
1.30. "Organitech Financial Statements" shall have the meaning assigned to
it in Section 4.20 hereof.
1.31. "Organitech Group Shares" shall mean all of the Organitech Shares
except those shares owned by Incubate.
1.32. "Organitech Shares" shall mean all shares of Organitech ordinary
shares issued and outstanding as of the Closing Date.
1.33. "Proprietary Information" shall mean the confidential information
about a party furnished by it, or on its behalf, to any other party; provided,
however, that Proprietary Information shall not include information which (i) is
or becomes generally available to the public other than as a result of a
disclosure by the receiving party in violation of this Agreement, (ii) was
available to the receiving party on a non-confidential basis prior to its
disclosure by the disclosing party, or (iii) becomes available to Incubate on a
non-confidential basis from a person other than the disclosing party who is not
otherwise bound by a confidentiality agreement with the disclosing party.
1.34. "SEC" shall mean the United States Securities and Exchange
Commission.
1.35. "SEC Documents" shall have the meaning set forth in Section 5.33.
1.36. "Securities Act" shall mean the Securities Act of 1933, as amended,
and the rules and regulations thereunder.
1.37. "Survival Period" shall have the meaning assigned to it in Section
9.4 hereof.
1.38. "Taxes" shall mean (i) all taxes, charges, fees, levies or other
assessments including, without limitation, all net income, gross income, gross
receipts, sales, use, ad valore, transfer, franchise, profits, payroll,
employment, social security, unemployment, excise, estimated, stamp, occupancy,
occupation, property or other similar taxes, including any interest or penalties
thereon, and additions to tax or additional amounts imposed by any federal,
state, local or foreign governmental authority, domestic or foreign, or (ii) all
liability for the payment of any taxes, interest, penalty, addition to tax or
like additional amount resulting from the application of Treasury Regulation
ss.1.1502-6 or comparable law or regulation.
1.39. "Tax Returns" shall mean any federal, state and local income and
sales tax returns which are required to be filed any party.
2. EXCHANGE OF SHARES
2.1. The Exchange . Subject to the terms and conditions contained in this
Agreement, effective upon the Closing on the Closing Date, the Organitech
Shareholders shall sell, assign, transfer and deliver to Incubate the Organitech
Group Shares in exchange for Seven Million Five Hundred Thousand 7,500,000)
shares of common stock (the "Incubate Exchange Shares"), free and clear of all
Liens, such that Organitech shall become a wholly-owned subsidiary of Incubate.
The Incubate Exchange Shares shall constitute at least 62.5% of Incubate's
issued and outstanding shares of capital stock following their issuance.
3. CLOSING
3.1. General. Unless otherwise agreed to by the parties hereto, the closing
under this Agreement (the "Closing") will be held at Pepper Hamilton LLP, 1201
Market St., Wilmington, Delaware, USA.
3.2. Deliveries. At the Closing and as a condition to Closing:
3.2.1. The Organitech Shareholders and Organitech will deliver to Incubate:
3.2.1.1 Share Transfer Deeds properly executed evidencing all of the
Organitech Group Shares, properly endorsed by the respective Organitech
Shareholders, free and clear of any Liens and accompanied by such stock powers
and other documents as may be necessary to transfer record ownership of the
Organitech Group Shares into Incubate's name;
3.2.1.2 All of the Books and Records of Organitech from the date of its
formation to the present;
3.2.1.3 Resignations of all of the officers and directors of Organitech;
3.2.1.4 An estoppel certificate in form and substance reasonably
satisfactory to Incubate executed by each of the Organitech shareholders listed
on Schedule 3.2.1.4 hereto (which list shall include all Organitech's
shareholders immediately prior to Closing hereunder) confirming, among other
things, that (1) its/his sole rights with regard to Organitech are attributable
to its/his ownership of the Organitech's shares; and (2) it/he has no other
claims against, or rights in or against Organitech (including, without
limitations, registration or other preference rights) and against any other
shareholder, director or office holder; and (3) its rights attributable to its
ownership of the Organitech Group Shares do not prevent or negate any of the
transactions contemplated herein; and (4) the Company has no agreements,
obligations, or promises, whether written or oral, with any of them.
3.2.1.5 An opinion letter of Organitech's Israeli counsel, dated as of the
Closing Date, substantially set forth in Section 7.7 hereof; and
3.2.1.6 All other agreements, certificates, consents, approvals and
documentary evidence required to be delivered pursuant to the Organitech
Shareholders' obligations hereunder.
3.2.2. Incubate will deliver to Organitech Shareholders:
3.2.2.1 Certificates evidencing the Incubate Exchange Shares, and evidence
of the recording of the ownership of the Incubate Exchange Shares by the
respective Organitech Shareholders', in the amounts proportional to their
respective holding of the Shares as listed on Schedule 3.2.2.1, in Incubate's
stock ledger;
3.2.2.2 Board resolutions authorizing the issuance of the Incubate Exchange
Shares to the respective Organitech Shareholders;
3.2.2.3 The written resignation, effective upon the Closing Date, of all
directors and officers of Incubate, except that of the Organitech Shareholders
designees listed on Schedule 3.2.2.3, dated subsequent to the Board resolutions
described in the preceding paragraph;
3.2.2.4 Evidence reasonably satisfactory to the Organitech Shareholders and
their legal counsel that all of Incubate's available cash may be used for
contribution to Organitech for use in its Business;
3.2.2.5 Audited financial statements of Incubate filed with the SEC;
3.2.2.6 A certificate from Sharone Perlstein certifying as to the
representations and warranties of Incubate in Section 5 hereof;
3.2.2.7 An estoppel certificate in form and substance reasonably
satisfactory to the Organtiech Shareholders executed by each of the Incubate
inside shareholders listed on Schedule 3.2.2.7 hereto (which list shall include
all Incubate's shareholders immediately prior to Closing hereunder, other than
the public shareholders (the "Incubate Public Shareholders") which Incubate has
represented constituting less than 2% of Incubate's issued stock as of Closing)
confirming, among other things, that (1) its/his sole rights with regard to
Incubate are attributable to its/his ownership of the Incubate's shares; and (2)
it/he has no other claims against, or rights in, Incubate (including, without
limitations, registration or other preference rights); and against any other
shareholder, director or office holder; and (3) its rights attributable to its
ownership of the Incubate shares do not prevent or negate any of the
transactions contemplated herein; and (4) the Company has no agreement,
obligations, or promises, whether written or oral, with any of them.
3.2.2.8 An opinion letter of Incubate's counsel, dated as of the Closing
Date, substantially in form set forth in Sestion 8.7 hereof; and
3.2.2.9 All other agreements, certificates, consents, approvals and
documentary evidence required to be delivered pursuant to the Incubate's
obligations hereunder.
3.2.2.10 Evidence satisfactory to the Organitech Shareholders under which,
at the time of Closing, Incubate does not own any assets other than cash in the
bank, and that Incubate is not engaged in any business other than being a
shareholder of Organitech and has no liabilities other than those set forth on
Schedule 3.2.2.10 attached hereto.
3.2.2.11 All of the Books and Records of Incubate from the date of its
formation to the present;
3.3. Expenses. Except as otherwise expressly provided herein, each party
shall bear its own costs incurred in connection with the negotiation, execution
and delivery of this Agreement and consummation of the transactions contemplated
hereby.
Subsequent Documentation. Each party hereto shall at any time and from time
to time upon the request of any other party hereto execute, acknowledge and
deliver, or cause to be executed, acknowledged and delivered, all such further
assignments, instruments of sale and transfer and other documents as may be
reasonably required to fully effectuate the transactions contemplated herein.
3.5 Incubate Warrants. The Incubate Warrants shall expire and be of no
further effect as of Closing.
4. REPRESENTATIONS AND WARRANTIES RESPECTING ORGANITECH.
The parties specified in each of the following sub-sections hereby,
severally, make the following representations and warranties to Incubate, each
of which shall survive the Closing and expire only in accordance with Section
9.4 hereof:
4.1. Organization, Power and Authority . Organitech and the Founding
Organitech Shareholders represent that Organitech is a corporation duly
organized, validly existing and in good standing under the laws of Israel.
Organitech has full corporate power and corporate authority, and all material
governmental permits, licenses and consents, to carry on the businesses in which
it is engaged and to own and use the properties owned and used by it. Organitech
does not own any equity interest in any corporation or other entity. Organitech
has the power and authority to own its property and to carry on its business as
presently conducted, and Organitech has the right, power, authority and capacity
to enter into and perform this Agreement and to carry out the transactions
contemplated hereby. Organitech has the right, power, authority and capacity to
enter into any agreements contemplated hereby and to perform its obligations
hereunder. Correct and complete copies of the [Memorandum and Articles of
Association ("Incorporation Documents").] of Organitech, as amended to date,
have been previously delivered to Incubate.
4.2. No Violation. Organitech represents that Organitech is not in
violation of any term of its Incorporation Documents, as amended to date, or any
agreement, instrument, judgment, decree, order, statute, rule or governmental
regulation applicable to it.
4.3. Restrictions. Each of the Organitech Shareholders, in his or its
capacity as a shareholder of Organitech, hereby declares, represents and
warrants that any restrictions on the sale and transfer of the Organitech Group
Shares have been duly observed and that this Agreement is full evidence thereof.
4.4. Authorization . Organitech and each of the Organitech Shareholders
represent that this Agreement constitutes the valid and binding obligation of
the Organitech Shareholders and Organitech, enforceable against each of them in
accordance with its terms. The execution, delivery and performance of this
Agreement has been duly authorized by all necessary corporate action of
Organitech, and by all necessary corporate actions on the part of each of the
Organitech Shareholders.
4.5. Capitalization of Organitech . Organitech and each of the Organitech
Shareholders represent that: Organitech's authorized capital stock (the
"Organitech Shares") consists of 3,000,000 shares of Ordinary Shares, of which
97,143 shares are issued and outstanding and owned of record and beneficially by
the Organitech Shareholders in the respective amounts listed on Schedule 4.5,
and 500,000 Preferred Shares, of which 12,460 are issued and outstanding and, to
the knowledge of Organitech, owned beneficially and as of record by Incubate.
The Organitech Shares have been validly issued, fully paid and nonassessable and
none of the Organitech Shares have been issued in violation of any preemptive or
similar right. Except for the Organitech Shares, the warrants held by Incubate,
and the employee stock options, Organitech has issued no other shares of capital
stock, there are no outstanding warrants, options or other rights, commitments,
agreements or understandings to purchase or acquire any shares of capital stock
or other equity securities of Organitech, and there are no outstanding debt
securities of the Organitech convertible into equity securities or otherwise
containing equity provisions. [Except as set forth in Schedule 4.5,] there are
no restrictions on the transfer of Organitech's capital stock to Incubate other
than those arising from applicable securities laws and the Chief Scientist
Office.
4.6. Each of the Organitech Shareholders represent that he has not entered
into or granted any outstanding warrants, options, commitments, agreements or
understandings with any person or entity (except for the transactions
contemplated by this Agreement) to sell, transfer or otherwise dispose of any of
the Organitech Group Shares.
4.7. The Founding Organitech Shareholders represent that Organitech is not
under any obligation whatsoever to issue any further shares or debentures and no
resolution to that effect has been passed in respect of Organitech, other than
to its employees under stock option plans which at the time of Closing shall be
exchanged for options of Incubate.
4.8. Title to Shares . The Organitech Shareholders represent that the
Organitech Shareholders have good and valid title to the Organitech Group
Shares, free and clear of all Liens [(except for any Liens disclosed on Schedule
4.8, each of which Liens will be discharged at the Closing)]. Upon delivery of
the Organitech Group Shares to Incubate and receipt in exchange therefore of the
Incubate Exchange Shares pursuant hereto, good and valid title to the Organitech
Group Shares, free and clear of all Liens, will pass to Incubate.
4.9. Subsidiaries; Investments in Other Entities . Organitech and the
Founding Organitech Shareholders represent that Organitech has no direct or
indirect investments in, and is not a party to any agreement, commitment or
understanding requiring Organitech to purchase or acquire any interest in, the
equity of any corporation, trust, partnership or business entity, or debt
securities convertible into such securities or otherwise containing equity
provisions.
4.10. No Conflicts; Absence of Restrictions . Organitech and the Organitech
Shareholders represent that except for third parties' consents which
will be obtained prior to Closing, the execution, delivery and performance of
this Agreement by the Organitech Shareholders and Organitech will not (i)
contravene any provision of the Organitech's [Incorporation Documents, (ii)
result in a breach of, or constitute a default under, any agreement or other
document to which the Organitech Shareholders or Organitech is a party or by
which the Organitech Shareholders or Organitech is bound, or any decree, order
or rule of any domestic or foreign court or governmental agency or any provision
of applicable law which is binding on the Organitech Shareholders or Organitech
or on any of the Organitech Group Shares, or (iii) result in the creation or
imposition of any mortgage, Lien, assessment, or restriction of any nature on
any of the Organitech Group Shares or give to others any interest or rights
therein or create in any third party the right to modify, terminate or
accelerate (or to make a claim for damages in respect of) any instrument or
contract to which the Organitech Shareholders or Organitech is a party or by
which the Organitech Shareholders or Organitech is bound.
4.11. Government and Third-Party Approvals . Organitech and the Organitech
Shareholders represent that [except for the approval by the Chief Scientist
Office or as listed on Schedule 4.11 attached hereto,] no consent by, approval
or authorization of or filing, registration or qualification with any
Governmental Entity, or any corporation, person or other entity (including any
party to any contract or agreement with the Organitech Shareholders or
Organitech) is required (i) for the execution, delivery and performance of this
Agreement by the Organitech Shareholders and Organitech, (ii) in connection with
the consummation of the transactions contemplated hereby and thereby by either
the Organitech Shareholders or Organitech, or (iii) in order to vest in Incubate
good and marketable title in and to all of the Organitech Group Shares upon the
Closing.
4.12. Title to Assets; Adequacy of Assets . Organitech represents that it
has good and marketable title to its properties and assets, whether tangible or
intangible, and whether consisting of real or personal property, including,
without limitation copyrights, patents, trademarks and other intangibles (if
any) which it purports to own, as well as all of the properties and assets
reflected in the FY 1999 Organitech Balance Sheet and those acquired since the
date thereof (except in each case for properties and assets sold or otherwise
disposed of in the ordinary course of business consistent with past practice
since the date thereof). On the Closing Date, Organitech will have good and
marketable title to its properties and assets reflected in the Closing Date
Balance Sheet. Except as set forth on Schedule 4.12, no property used by
Organitech in connection with the Business is located other than in the
possession of Organitech. All leases of personal property to which Organitech is
a party, are fully effective and afford Organitech peaceful and undisturbed
possession of the subject matter of the lease.
4.13. Cash Accounts . Organitech represents that Schedule 4.13 lists each
bank and mutual fund account and safe deposit box of Organitech and each person
authorized to sign checks or withdraw funds from such accounts and to have
access to such safe deposit boxes.
4.14. [Reserved]
4.15. [Reserved].
4.16. [Reserved]
4.17. Intellectual Property and Information . Organitech and the Organitech
Shareholders represents that no claim is pending or, to their knowledge,
threatened to the effect that: (i) the present or past operations of the
Business infringe upon or conflict with the asserted rights of any other person
in respect of any Intellectual Property and Information or (ii) any Intellectual
Property and Information is invalid or unenforceable.
4.18. No Infringement. Organitech represents that to the best of its
knowledge (without conducting a patent search), none of the patents, trademarks,
trade names, service marks, copyrights, computer programs or trade secrets
included within the Intellectual Property and Information infringes on the
rights of third parties.
4.19. [Reserved].
4.20. Organitech Financial Statements .
4.20.1. Incubate acknowledges that Organitech is a start-up company and has
therefore no significant reportable financial information. Organitech shall have
delivered to Incubate at or prior to Closing a balance sheet and a statement of
income and retained earnings and statement of cash flow as of the most recent
completed quarter (referred to collectively as the "Organitech Financial
Statements").
4.20.2. Organitech and Hessel represent that the Organitech Financial
Statements shall fairly present the financial condition and the results of the
operations Organitech as at the date thereof and for the periods reported
therein.
4.20.3. To the knowledge of Organitech and Hessel, Organitech has no
Liabilities except as reflected in the Organitech Financial Statements or any
Liabilities which arose after the date of the Agreement in the ordinary course
of business of Organitech and in compliance with the covenants and agreements of
Organitech herein contained.
4.21. Affiliated Relationships . Organitech represents that all services
rendered and all goods sold by (i) Organitech to any of the Organitech
Shareholders or any Affiliate(s) of the Organitech Shareholders, or (ii) by any
of the Organitech Shareholders or any Affiliate(s) of the Organitech
Shareholders to Organitech, have been recorded in the accounts of Organitech at
their full value as if they were transferred in arm's length transactions.
4.22. Permits and Approvals . Organitech represents that Schedule 4.22
contains a true and correct description of all licenses, permits, approvals,
authorizations, consents and registrations issued in favor of Organitech, all of
which are in full force and effect and the Business is currently being operated
in compliance in all material respects with the terms of each of the foregoing.
4.23. Compliance with Law . Organitech represents that except as disclosed
in Schedule 4.23, Organitech has complied in all material respects with each,
and are not in violation of any, law, ordinance or governmental rule or
regulation to which Organitech is subject and has not failed to obtain, or to
adhere in all material respects to the requirements of, any license, permit or
authorization necessary to the ownership of its assets or the operation of the
Business.
4.24. [Reserved]
4.25. Litigation . Organitech represents that no litigation, arbitration,
investigation or other proceeding of or before any court, arbitrator or
governmental or regulatory official, body or authority is pending or, to the
knowledge of Organitech, threatened against Organitech or the transactions
contemplated by this Agreement, and Organitech has no knowledge of any basis for
any such litigation, arbitration, investigation or proceeding. Organitech is not
a party to or subject to the provisions of any judgment, order, writ,
injunction, decree or award of any court, arbitrator or governmental or
regulatory official, body or authority.
4.26. Conduct of Business . Organitech represents that since the date of
the Organitech Financial Statement, the Business has been conducted only in the
ordinary course and in a manner consistent with past practices.
4.27. [Reserved] .
4.28. Contracts, Leases, Etc.
Organitech represents that [except as listed and described on Schedule 4.28 or
any other Schedule attached hereto,] Organitech is not a party to any written
Contracts of the type described below:
4.28.1. agreement or commitment with any current or former shareholder,
director, or officer, or any of their Affiliates;
4.28.2. agreement or commitment to sell or supply products or to perform
services which obligates Organitech to sell products or perform services which
involves in any one case $[10,000] which is not cancelable on thirty (30) days
notice or less without penalty;
4.28.3. ease under which Organitech is either lessor or lessee of personal
property requiring annual lease payments (including rent and any other charges)
in excess of $[10,000], and any lease under which Organitech is the lessor of
real property;
4.28.4. note, debenture, mortgage, pledge, charge, security agreement,
bond, conditional sale agreement, equipment trust agreement, letter of credit
agreement, loan agreement or other contract or commitment for borrowing or
lending of money (including, without limitation, loans to or from current or
former officers, directors, shareholders or any member of their Affiliates),
agreement or arrangements for a line of credit or guarantee, pledge or
undertaking of the indebtedness of any other person;
4.28.5. agreement, contract or commitment for any capital expenditure in
excess of $[10,000];
4.28.6. agreement, contract or commitment limiting or restraining it from
engaging or competing in any lines of business with any person;
4.28.7. license, franchise, distributorship or other similar agreement,
including those which relate in whole or in part to any patent, trademark,
tradename, service mark or copyright or to any ideas, technical assistance or
other know-how of or used by it in the operation of its Business;
4.28.8. power of attorney granted by Organitech in favor of any person or
entity;
4.28.9. other agreement requiring payments or other consideration by or
from Organitech in excess of $[10,000] during the remainder of its term; or
4.28.10. licensing arrangements, joint ventures and royalty and franchise
agreements.
4.28.11. Organitech, and to the knowledge of Organitech, the other parties
thereto, are in compliance with the provisions of each of the Contracts; neither
Organitech nor, to the knowledge of Organitech, any of the other parties
thereto, are in default in the performance, observance or fulfillment of any
obligation, covenant or condition contained therein; and no event has occurred
which with or without the giving of notice or lapse of time, or both, would
constitute a default thereunder by Organitech, and any other party.
4.29. [Reserved].
4.30. Tax Audit and Returns . Organitech represents that Organitech has
duly and timely filed all Tax Returns and has paid all Taxes shown thereon.
Organitech has made sufficient provision for the payment of all Taxes required
to be accrued which are not yet payable as of the Closing. The Tax Returns are
true, complete and correct in all respects. No deficiency in the payment of any
Taxes for any period to the date hereof has been assessed against the Organitech
by any taxing authority which has not been discharged in full.
4.31. [Reserved] .
4.32. [Reserved] .
4.33. [Reserved] .
4.34. Transactions with Affiliates . Organitech represents that there are
no contracts, obligations or arrangements between Organitech and any current
director, officer, shareholder or employee of Organitech or any Affiliate of any
such person [except for those identified on Schedule 4.34 or another Schedule
hereto, a complete copy of each of which (including all amendments) has been
delivered to Incubate]. [Except as set forth on Schedule 4.34,] Organitech is
not indebted to any of the the Organitech Shareholders or any of their
Affiliates.
4.35. Compensation to Employees, Etc. . Organitech represents that Schedule
4.35 lists each of its Employees. In addition, Schedule 4.35 lists (i) the base
salary, as currently in effect, for each Employee, (ii) the bonus arrangements,
if any, currently in effect for each of such Employees, (iii) the commission
arrangements, if any, currently in effect for each of such Employees and (iv)
the date on which the most recent salary increase went into effect for each of
such Employees and the amount of each such increase. There are no Contracts
(including, without limitation, collective bargaining agreements) with any
officer, director, employee or independent contractor of the Company or any of
its Subsidiaries[, except as set forth on Schedule 4.35]. There are no pension
plans or profit sharing plans, commission agreements, bonus, stock options,
other plans, agreements or arrangements providing for any officer, director,
employee or independent contractor of the Organitech to receive any remuneration
or other benefit[, except as set forth on Schedule 4.35]. There is not pending
or, to the knowledge of Organitech , threatened any labor dispute or work
stoppage involving any employee or independent contractor of, or affecting the
Business, or any obligation to continue the employment or engagement of any of
the officers, directors or employees of Organitech[, except as set forth on
Schedule 4.35].
4.36. [Reserved].
4.37. [Reserved].
4.38. Investment Representation . Each Organitech Shareholder represents
and warrants to and for the benefit of Incubate as follows:
4.38.1. He or it is acquiring the Incubate Exchange Shares hereunder for
its own account, for investment and not with a view to the distribution thereof
within the meaning of the Securities Act;
4.38.2. He or it, together with his or its financial advisors, have such
knowledge and experience in business and financial matters so as to enable him
or it to understand and evaluate the risks of his or its investment in the
Incubate Exchange Shares and to form an investment decision with respect
thereto.
4.38.3. He or it understands that Incubate is not obligated to register the
Shares under the Securities Act and, accordingly, that the Shares to be sold to
him or it hereunder may have to be held indefinitely by him or it unless so
registered under the Securities Act or unless an exemption from the registration
provisions of the Securities Act is available.
4.38.4. He or it, together with his or its attorneys and financial
advisers, have been afforded the opportunity during the course of negotiating
the transactions contemplated by this Agreement (i) to review, and have
reviewed, such documents and written materials related to Incubate, its business
and operations, and (ii) to ask, and have asked, questions of, and to secure
such information from, Incubate and its respective officers and directors as he
or it deems necessary to evaluate the merits and risks of entering into this
Agreement and receiving the Incubate Exchange Shares in connection herewith.
4.39. Corporate Records . Organitech represents that the corporate books
and records of the Organitech have been maintained in accordance with applicable
law, and fairly record and reflect all transactions material to the operations
of Organitech.
4.40. Statements and Other Documents Not Misleading . Organitech represents
that neither this Agreement, including all schedules and exhibits hereto, nor
any other financial statement, document or other instrument heretofore or
hereafter furnished by Organitech or the Organitech Shareholders to Incubate in
connection with the transactions contemplated hereby contains or will contain
any untrue statement of any material fact or omits or will omit to state any
material fact required to be stated in order to make such statement, document or
other instrument not misleading.
4.41. Statements True. Each of the Organitech Shareholders represents as to
himself or itself that no financial statement, document or other instrument
heretofore or hereafter furnished by each such Organitech Shareholder to
Incubate authorizing the transactions contemplated hereby contains or will
contain any untrue statement of any material fact or omits or will omit to state
any material fact required to be stated in order to make such statement,
document or other instrument not misleading.
4.42. Outside Organitech Shareholders. Anything set forth herein to the
contrary notwithstanding, the Outside Organitech Shareholders have not, and
shall not be deemed to have, made any representations, warranties, statements or
covenants whatsoever to any other party hereto in connection with the
transactions contemplated hereby, except for the representations set forth in
Sections 4.4 and 4.6 above (which representations shall be severally with
respect to each respective shareholder's shares) and their sole and limited
obligation hereunder shall be to transfer at Closing to Incubate their
respective shares in Organitech in exchange for the issuance to each of them of
the Incubate Exchange Shares as contemplated herein.
5. REPRESENTATIONS AND WARRANTIES RESPECTING INCUBATE
Incubate and Perelstein hereby make the following
representations and warranties to Organitech and the Organitech Shareholders,
each of which shall survive the Closing and expire only in accordance with
Section 9.4 hereof:
5.1. Organization, Power and Authority . Incubate is a corporation duly
formed, validly existing and in good standing under the laws of the State of
Colorado. Incubate is not qualified to do business as a foreign corporation in
any jurisdiction other than the State of Florida, and such qualification is not
presently required. Incubate has full corporate power and corporate authority,
and all material government permits, licenses and consents, to carry on the
business in which it is engaged and to own and use the properties owned and used
by it. At Closing, Incubate will not own any equity interest in any corporation
or other entity other than Organitech.
5.2. Due Authorization . The execution and delivery of this Agreement
by Incubate and performance of the obligations of Incubate contemplated hereby
have been duly and validly authorized by all necessary corporate action.
Incubate has the right, power and authority to enter into and perform this
Agreement and any other agreements contemplated hereby, and this Agreement
constitutes the valid and binding obligations of Incubate, enforceable against
Incubate in accordance with its terms.
5.3. Issuance of Shares. Each of the Incubate Exchange Shares are duly
authorized and, upon issuance in accordance with the terms of this Agreement,
will be validly issued, fully paid and nonassessable, free from all taxes,
liens, claims, encumbrances and charges with respect to the issue thereof, will
not be subject to preemptive rights or other similar rights of shareholders of
Incubate, and will not impose personal liability on the holders thereof. No
further approval or authority of the shareholders or the Board of Directors of
Incubate is required for issuance and transfer of the Incubate Exchange Shares
as contemplated in this Agreement. Subject to the accuracy of the Organitech
Shareholders' representations and warranties in Section 4 of this Agreement, the
issuance and transfer of the Incubate Exchange Shares in conformity with the
terms of this Agreement constitute transactions exempt from the registration
requirements of Section 5 of the Securities Act.
5.4. Capitalization of Incubate. The authorized capital stock of
Incubate consists of (a) 800,000,000 shares of common stock, of no par value per
share, of which only 4,500,000 will be issued and outstanding at Closing(the
"Incubate Shares") and (b) 100,000,000 shares of preferred stock none of which
are issued. The Incubate Shares have been validly issued, are fully paid,
nonassessable, free of Liens, options, restrictions and legal or equitable
rights of others not a party to this Agreement and have been issued in
compliance with all federal and state securities laws. None of the Incubate
Shares have been issued in violation of any preemptive or similar right. Except
for the Incubate Shares, Incubate has issued no other shares of capital stock,
there are no outstanding warrants, options or other rights, commitments,
agreements or understandings to purchase or acquire any shares of capital stock
or other equity securities of Incubate, and there are no outstanding debt
securities of Incubate convertible into equity securities or otherwise
containing equity provisions. Incubate has not reserved any of its authorized
shares of capital stock for any purpose. There are no restrictions on the
transfer of Incubate's capital stock other than those arising from federal and
state securities laws, and (b) except for this Agreement, Incubate has no
understandings or agreements with any person or entity respecting Incubate's
capital stock or other securities of the Incubate. Except as contemplated by
this Agreement, Incubate is not under any obligation whatsoever to issue any
further shares or debentures and no resolution to that effect has been passed in
respect of Incubate. Immediately following the Closing, there will be
______________ shares of common stock issued and outstanding, the ownership of
which is set forth in Schedule 5.4. [4.5M shares to pre-closing Incubate
shareholders, 7.5M shares to Organitech Shareholders, and 1M to employees of
Organitech under their stock options] All of the shareholders of Incubate have
valid title to such shares and acquired their Incubate shares in a lawful
transaction and in full compliance with all federal laws and state laws
(including the respective securities laws). None of Incubate's issued shares,
except for shares owned by the Incubate Public Shareholders, are or shall become
tradable prior to May of 2001.
5.5. Subsidiaries; Investments in Other Entities. Except for those
ownership interests expressly identified in Schedule 5.5, Incubate has no direct
or indirect investments in, and is not a party to any agreement, commitment or
understanding requiring Incubate to purchase or acquire any interest in, the
equity of any corporation, trust, partnership or business entity, or debt
securities convertible into such securities or otherwise containing equity
provisions. At Closing, Incubate shall have no subsidiaries or interests in
entities other than Organitech.
5.6. No Conflicts; Absence of Restrictions. The execution, delivery and
performance of this Agreement by the Incubate will not (i) contravene any
provision of Incubate's Articles of Incorporation or Bylaws, (ii) result in a
breach of, or constitute a default under, any agreement or other document to
which Incubate is a party or by which Incubate is bound, or any decree, order or
rule of any domestic or foreign court or governmental agency or any provision of
applicable law which is binding on Incubate or on any of the Incubate Exchange
Shares or any of Incubate's assets, or (iii) result in the creation or
imposition of any mortgage, Lien, assessment, or restriction of any nature on
any of the Incubate Exchange Shares or any of Incubate's assets or give to
others any interest or rights therein or create in any third party the right to
modify, terminate or accelerate (or to make a claim for damages in respect of)
any instrument or contract to which Incubate is a party or by which Incubate is
bound.
Incubate is not in violation of its Articles of Incorporation or
Bylaws, and Incubate is not in default (and no event has occurred which with
notice or lapse of time or both could put Incubate in default) under any
agreement, indenture or instrument to which Incubate is a party or by which any
property or assets of Incubate are bound or affected. Incubate is not conducting
its business in violation of any law, ordinance or regulation of any
Governmental Entity. Except as specifically contemplated by this Agreement and
as required under the Securities Act and any applicable state securities laws or
any listing agreement with any securities exchange or automated quotation
system, Incubate is not required to obtain any consent, authorization or order
of, or make any filing or registration with, any court or governmental agency or
any regulatory or self-regulatory agency in order for it to execute, deliver or
perform any of its obligations under this Agreement in accordance with the terms
hereof, or to issue and transfer the Incubate Exchange Shares in accordance with
the terms hereof. In the case of the issuance and transfer of the Incubate
Exchange Shares, all consents, authorizations, orders, filings and registrations
which Incubate is required to obtain pursuant to the preceding sentence have
been obtained or effected on or prior to the date hereof.
5.7. Title to Properties and Assets; Liens, etc. Incubate has good and
marketable title to its properties and assets, in each case subject to no
mortgage, Lien or lease, other than the lien of current taxes not yet due and
payable. At Closing, the only assets of Incubate shall be Cash in an amount no
less than [$3,000,000] and shares in Organitech.
5.8. Incubate Financial Statements. Incubate has delivered to
Organitech audited consolidated financial statements of Incubate (including
balance sheet and profit and loss statement) for the periods ended [December 31,
1998, 1999 and June 30, 2000 YTD] (collectively, the "Incubate Financial
Statements"). The Incubate Financial Statements have been prepared in accordance
with GAAP. The Incubate Financial Statements fairly present the financial
condition and operating results of Incubate as of the dates, and for the
periods, indicated therein. Except as set forth in the Incubate Financial
Statements, Incubate has no material liabilities, contingent or otherwise, other
than (i) liabilities incurred in the ordinary course of business subsequent to
[June 30, 2000] and (ii) obligations under contracts and commitments incurred in
the ordinary course of business and not required under GAAP to be reflected in
the Incubate Financial Statements, which, in both cases, individually or in the
aggregate are not material to the financial condition or operating results of
Incubate. Except as disclosed in the Incubate Financial Statements, Incubate is
not a guarantor or indemnitor of any indebtedness of any other person, firm or
corporation.
5.9. Absence of Certain Changes. Since June 30, 2000, there has not been
(a) any material adverse change in or affecting the condition, financial or
otherwise, or in the earnings or assets of Incubate, whether or not arising in
the ordinary course of business, (b) any transactions entered into by Incubate,
other than those in the ordinary course of business, which are material with
respect to Incubate, (c) any dividend or distribution of any kind declared, paid
or made on the capital stock of Incubate, or (d) any loss or damage (whether or
not insured) to the physical property or assets of Incubate which has a material
adverse effect.
5.10. Material Contracts and Commitments. Neither Incubate, nor to
Incubate's knowledge, any third party, is in default under any contract,
agreement or instrument to which Incubate is a party.
5.11. Employees. Incubate does not have, and at Closing will not have, any
employee. No prior employee of Incubate has any claim whatsoever against
Incubate arising out of such employment.
5.12. Governmental Consent, etc. No consent, approval or authorization of,
or designation, declaration or filing with, any governmental authority on the
part of Incubate is required in connection with the valid execution and delivery
of this Agreement or the consummation of any other transaction contemplated
hereby, except (a) qualification (or taking such action as may be necessary to
secure an exemption from qualification, if available) of the issuance and
transfer of the Incubate Exchange Shares under the applicable Blue Sky laws,
which filing and qualification, if required, will be accomplished in a timely
manner prior the Closing [Form D?]. Incubate has all governmental permits,
business and other approvals necessary to conduct business as currently and
proposed to be conducted.
5.13. Disclosure. This Agreement and the Schedules attached hereto, when
taken together, do not contain and will not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
made herein, in light of the circumstances under which they were made not
misleading.
5.14. Absence of Liabilities . Incubate has no Liabilities except as set
forth on Schedule 5.14 hereto, all of which are reflected in the Incubate
Financial Statements.
5.15. Affiliated Relationships . All services rendered and all goods sold
by Incubate to any of its directors, officers, shareholders, or any Affiliate(s)
of the foregoing, have been recorded in the accounts of Incubate at their full
value as if they were transferred in arm's length transactions. At Closing,
there shall be no outstanding agreement between Incubate, on the one hand, and
any other person, on the other hand, including without limitation any
employment, consulting, warrant, option, registration right or preemptive right
agreement [except for the written agreement entered into prior to the date
hereof and specifically identified on Schedule 5.15 attached hereto]. Without
limiting the generality of the foregoing , the shareholders of
Incubate have no claims or right of action whatsoever against or from Incubate,
either as directors, officers, shareholders, investors, employees or otherwise
and any right that may have accrued to any of the shareholders of Incubate (in
whatever capacity), whether at law, in equity or pursuant to any agreement, has
been (or will be) fully satisfied or waived in writing ,prior to Closing.
5.16. Real Property, Environmental and Safety Laws. Incubate owns no
real property. Incubate is not in violation of any applicable statute, law or
regulation relating to the environment or occupational health and safety, and no
material expenditures are or will be required in order to comply with any such
existing statute, law or regulation.
5.17. No Conflict of Interest; Guarantees. Incubate is not indebted,
directly or indirectly, or committed to make loans or extend credit, to any of
its shareholders, officers or directors or to any member of their immediate
family, in any amount whatsoever. None of Incubate's shareholders, officers or
directors, or any members of their immediate families, are, directly or
indirectly, indebted to Incubate or have any direct or indirect ownership
interest in any firm or corporation with which Incubate in affiliated or with
which Incubate has a business relationship, or any firm or corporation which
competes with Incubate. None of Incubate's shareholders, officers or directors
or any members of their immediate families are directly or indirectly interested
in any material contract with Incubate. Incubate is not a guarantor or
indemnitor of any indebtedness of any other person, firm or corporation.
5.18. No Conflicts; Absence of Restrictions. The execution, delivery
and performance of this Agreement by Incubate will not (i) contravene any
provision of the Incubate's Articles of Incorporation or Bylaws, (ii) result in
a breach of, or constitute a default under, any agreement or other document to
which Incubate is a party or by which Incubate is bound, or any decree, order or
rule of any domestic or foreign court or governmental agency or any provision of
applicable law which is binding on Incubate or on any of the Incubate Exchange
Shares or any of Incubate's assets, or (iii) result in the creation or
imposition of any mortgage, Lien, assessment, or restriction of any nature on
any of the Incubate Exchange Shares or any of Incubate's assets or give to
others any interest or rights therein or create in any third party the right to
modify, terminate or accelerate (or to make a claim for damages in respect of)
any instrument or contract to which Incubate is a party or by which Incubate is
bound.
5.19. No Violations.
5.19.1. Incubate is not in violation of its Articles of Incorporation or
Bylaws, and Incubate is not in default (and no event has occurred which with
notice or lapse of time or both could put Incubate in default) under any
agreement, indenture or instrument to which Incubate is a party or by which any
property or assets of Incubate are bound or affected.
5.19.2. Incubate is not conducting its business in violation of any law,
ordinance or regulation of any Governmental Entity.
5.19.3. Except as specifically contemplated by this Agreement and as
required under the Securities Act and any applicable state securities laws or
any listing agreement with any securities exchange or automated quotation
system, Incubate is not required to obtain any consent, authorization or order
of, or make any filing or registration with, any court or governmental agency or
any regulatory or self-regulatory agency in order for it to execute, deliver or
perform any of its obligations under this Agreement in accordance with the terms
hereof, or to issue and transfer the Incubate Exchange Shares in accordance with
the terms hereof. In the case of the issuance and transfer of the Incubate
Exchange Shares, all consents, authorizations, orders, filings and registrations
which Incubate is required to obtain pursuant to the preceding sentence have
been obtained or effected on or prior to the date hereof.
5.20. Title to Properties and Assets; Liens, etc. Incubate has good and
marketable title to its properties and assets, in each case subject to no
mortgage, Lien or lease.
5.21. [Reserved].
5.22. [Reserved].
5.23. [Reserved]
5.24. [Reserved]
5.25. [Reserved]
5.26. [Reserved]
5.27. Tax Audit and Returns . Incubate has duly and timely filed all Tax
Returns and has paid all Taxes shown thereon. Incubate has made sufficient
provision for the payment of all Taxes required to be accrued which are not yet
payable as of the Closing. The Tax Returns are true, complete and correct in all
respects. No deficiency in the payment of any Taxes for any period to the date
hereof has been assessed against the Incubate by any taxing authority which has
not been discharged in full.
5.28. Litigation . No litigation, arbitration, investigation or other
proceeding before any court, arbitrator or governmental or regulatory official,
body or authority is pending or threatened against Incubate relating to, or
impairing Incubate's ability to perform its obligations under, the transactions
contemplated by this Agreement, and Incubate does not know of any basis for such
litigation, arbitration, investigation or proceeding. Incubate is not in default
with respect to any judgment, order or decree of any court or governmental
agency or instrumentality.
5.29. Transfer Tax. On the Closing Date, all stock transfer or other taxes
(other than income taxes) which are required to be paid in connection with the
issuance and transfer to the Organitech Shareholders of the Incubate Exchange
Shares will be, or will have been, fully paid provided for by Incubate.
5.30. Commission . Neither Incubate nor anyone acting on its behalf has
made any agreement or taken any action which may cause anyone claiming through
Incubate to become entitled to a commission as a result of the purchase of the
Shares and the consummation of the other transactions pursuant to this
Agreement.
5.31. Financial Ability . Incubate has the financial resources to
consummate the transactions contemplated hereby. Performance by Incubate of its
obligations at Closing is not contingent on Incubate's obtaining outside
funding.
5.32. Investment Representation of Incubate . Incubate represents and
warrants to and for the benefit of the Organitech Shareholders and Organitech as
follows:
5.32.1. It is acquiring the Organitech Group Shares hereunder
for its own account, for investment and not with a view to the distribution
thereof within the meaning of the Securities Act of 1933 (the "Securities Act").
5.32.2. It, together with its financial advisors, have such
knowledge and experience in business and financial matters so as to enable it to
understand and evaluate the risks of its investment in the Organitech Group
Shares and to form an investment decision with respect thereto.
5.32.3. It understands that neither Organitech nor the
Organitech Shareholders are obligated to register the Organitech Group Shares
under the Securities Act or any other securities act and, accordingly, that the
Organitech Group Shares to be sold to it hereunder may have to be held
indefinitely by it unless so registered under applicable securities laws or
unless an exemption from the registration is available.
5.32.4. It, together with its attorneys and financial
advisers, have been afforded the opportunity during the course of negotiating
the transactions contemplated by this Agreement (i) to review, and have
reviewed, such documents and written materials related to Organitech, its
business and operations, and (ii) to ask, and have asked, questions of, and to
secure such information from, the Organitech Shareholders and Organitech and its
respective officers and directors as it deems necessary to evaluate the merits
and risks of entering into this Agreement and receiving the Organitech Group
Shares in connection herewith.
5.32.5. The Outside Organitech Shareholders have made no
representations to Incubate regarding Organitech, and Incubate has not relied on
any information it may have received from or on behalf of the Outside Organitech
Shareholders in its exchange of the Incubate Exchange Shares for the Organitech
Group Shares.
5.32.6. The Founding Organitech Shareholders made no
representations regarding Organitech other than those expressly made by them
herein, and Incubate has not relied on any information it may have received from
or on behalf of the Founding Organitech Shareholders in its exchange of the
Incubate Exchange Shares for the Organitech Group Shares.
5.33. SEC Documents, Financial Statements. Incubate has filed all
reports, schedules, forms, statements and other documents required to be filed
by it with the SEC pursuant to the reporting requirements of the Exchange Act
(all of the foregoing filed prior to the date hereof and all exhibits included
therein and financial statements and schedules thereto and documents (other than
exhibits) incorporated by reference therein, being hereinafter referred to as
the "SEC Documents"). Since the Original Date, and to Incubate and Perlstein's
knowledge also prior to the Original Date, all such filings of SEC Documents
were done timely. Incubate has delivered to the Organitech Shareholders, or the
Organitech Shareholders have had access to, true and complete copies of the SEC
Documents, except for such exhibits and incorporated documents. As of their
respective dates, the SEC Documents complied in all material respects with the
requirements of the Exchange Act or the Securities Act, as the case may be, and
the rules and regulations of the SEC promulgated thereunder applicable to the
SEC Documents, and none of the SEC Documents, at the time they were filed with
the SEC, contained any untrue statement of a material fact or omitted to state a
material fact required to be stated therein or necessary in order to make the
statements therein, in light of the circumstances under which they were made,
not misleading. As of their respective dates, the consolidated financial
statements of the Company included in the SEC Documents complied as to form in
all material respects with applicable accounting requirements and the published
rules and regulations of the SEC with respect thereto. Such financial statements
have been prepared in accordance with U.S. generally accepted accounting
principles, consistently applied, during the periods involved (except (a) as may
be otherwise indicated in such financial statements or the notes thereto, or (b)
in the case of unaudited interim consolidated statements, to the extent they may
not include footnotes or may be condensed or summary statements) and fairly
present in all material respects the consolidated financial position of Incubate
as of the dates thereof and the consolidated results of its operations and cash
flows for the periods then ended (subject, in the case of unaudited statements,
to normal year-end audit adjustments). Except as set forth in the financial
statements included in the SEC Documents, Incubate has no liabilities,
contingent or otherwise, other than (x) liabilities incurred in the ordinary
course of business subsequent to the date of such financial statements, (y)
liabilities of the type not required under generally accepted accounting
principles to be reflected in such financial statements, and (z) obligations
under contracts and commitments not required under generally accepted accounting
principles to be reflected in such financial statements. Such liabilities and
obligations would not, individually or in the aggregate, have a material adverse
effect.
5.34. Available Cash. Immediately following the Closing, Incubate shall
have Cash in an amount no less than Three Million U.S. Dollars (US$3,000,000).
All of Incubate's Cash or any other assets of Incubate shall be available
without restriction immediately following the Closing for contribution to
investment in Organitech.
5.35. Accounts Receivable. Incubate has no Accounts Receivable.
5.36. No Integrated Offering. All offers and sales of capital stock of
Incubate before the date of this Agreement were at all relevant time duly
registered under or exempt from the registration requirements of the Securities
Act and were duly registered or subject to an available exemption from the
registration requirements of the applicable state securities or Blue Sky laws.
Neither Incubate nor any of its affiliates, nor any person acting on its or
their behalf, has directly or indirectly made any offers or sales in any
security or solicited any offers to buy any security under circumstances that
would require registration under the Securities Act of the issuance of the
Incubate Exchange Shares to the Organitech Shareholders. The issuance of the
Incubate Exchange Shares to the Organitech Shareholders will not be integrated
with any other issuance of Incubate's securities (past, current or future) for
purposes of the Securities Act or any applicable rules of any stock exchange
applicable to Incubate.
5.37. Investment Company Status. Incubate is not and upon consummation
of the transfer and issuance of the Incubate Exchange Shares will not be an
"investment company," a company controlled by an "investment company" or an
"affiliated person" of, or "promoter" or "principal underwriter" for, an
"investments company" as such terms are defined in the Investment Company Act of
1940, as amended.
5.38. Offering Materials. Incubate has not taken any action to sell,
offer for sale or solicit offers to buy any securities of Incubate which would
bring the issuance and transfer of the Incubate Exchange Shares, as contemplated
by this Agreement, within the provisions of Section 5 of the Securities Act,
unless such offer, issuance or sale was or shall be within the exemptions of
Section 4 of the Securities Act.
5.39. OTCBB Compliance. Incubate's common stock, with no par value is
registered pursuant to Section 12(g) of the Exchange Act and is quoted on the
OTC Electronic Bulletin Board ("OTCBB"). The Company has taken no action
designed to terminate the registration of such common stock under the Exchange
Act or to terminate its registration from quotation on the OTCBB. Incubate is
not aware of, and has not received any notice of, any efforts or actions to
terminate the registration of such common stock under the Exchange Act or to
terminate its registration from quotation on the OTCBB.
5.40. No Power to Bind. Schedule 5.40 attached hereto sets forth the
names of all persons who had either express or apparent authority to bind
Incubate at any time since the Original Date. As of the date hereof and until
Closing, no person other than Perlstein shall have, or be granted, any authority
to bind Incubate.
5.41. Information Complete. Organitech Shareholders shall have received
prior to Closing from, or on behalf of, Incubate all of Incubate's books and
records related to Incubate's corporate, financial and business affairs.
5.42. Perlstein's Obligations. Perlstein's liability with respect to
representations and warranties set forth in this Section 5 related to matters
which occurred prior to the Original Date, shall be limited to Perlstein's
knowledge.
5.43. RISK FACTORS. INCUBATE IS ENTERING INTO THIS TRANSACTION BASED ON ITS
OWN ASSUMPTIONS, INVESTIGATIONS AND FORCASTS. INCUBATE HAS BEEN GIVEN ALL THE
INFORMATION REQUESTED AND DEEMED NECESSARY BY IT, INCLUDING ACCESS TO ORGANITECH
INTELLECTUAL PROPERTY, THE RIGHT TO RECEIVE INFORMATION FROM ORGANITECH'S PATENT
ATTORNEY, AND THE RIGHT TO OBTAIN AN OPINION FROM ITS OWN INTELLECTUAL PROPERTY
COUNSEL. INCUBATE IS AWARE THAT ORGANITECH IS A START UP COMPANY WHICH MAY OR
MAY NOT ALWAYS BECOME SUCCESSFUL. INCUBATE IS ALSO AWARE THAT THE BUSINESS OF
ORGANITECH RELATES TO A DIFFERENT APPROACH TO PRODUCTION OF AGRICULTURAL
PRODUCTS AND TO CONSUMERS' HABITS WHICH HAVE NOT BEEN TESTED AND MAY NOT BE
SUCCESSFUL. ORGANITECH AND THE FOUNDING ORGANITECH SHAREHOLDERS DISCLAIM ANY
EXPRESS OR IMPLIED PROMISE, REPRESENTATION AND/OR WARRANTY WITH RESPECT TO THE
FUTURE SUCCESS OF THE TECHNOLOGY AND/OR PROCESSES USED BY ORGANITECH AND/OR THE
MERCHANTABILITY OF THE TECHNOLOGY AND/OR THE COMMERCIAL SUCCESS OF ITS PRODUCTS
AND/OR THAT ORGANITECH WILL BE ABLE TO DEVELOP A PRODUCT FREE OF ANY INFRINGMENT
OF THIRD PARTY INTELLECTUAL PROPERTY RIGHT AND/OR THE SUITABILITY OF THE
TECHNOLOGY FOR REGULATROY APPROVALS AS MAY BE NECESSARY IN VARIOUS COUNTRIES FOR
THE MANUFACTURE, USE OR SALE OF PRODUCTS.
6. CERTAIN COVENANTS AND OTHER MATTERS.
6.1. Corporate Examinations and Investigations By Incubate . Between
the date hereof and the Closing Date, Organitech agrees to cooperate (and to
cause Organitech and its officers employees, consultants, agents, attorneys and
accountants to cooperate) fully with Incubate and with its counsel, accountants
and representatives in the conduct of their Due Diligence investigation of
Organitech from legal, environmental, insurance, valuation and solvency
perspectives and, in connection with such Due Diligence investigation, to grant
to Incubate and such representatives access to the properties, books and
records, contracts, employees, customers, creditors, landlords, vendors and
suppliers of Organitech (the "Incubate Due Diligence Investigation"). Incubate
will use its best efforts to complete the Incubate Due Diligence Investigation
as promptly as reasonably practicable.
6.2. Corporate Examinations and Investigations By Organitech . Between
the date hereof and the Closing Date, Incubate agrees to cooperate (and to cause
its officers employees, consultants, agents, attorneys and accountants to
cooperate) fully with Organitech and the Organitech Shareholders and with their
counsel, accountants and representatives in the conduct of their Due Diligence
investigation of Incubate from legal, environmental, insurance, valuation and
solvency perspectives and, in connection with such Due Diligence investigation,
to grant to Organitech, Organitech Shareholders and such representatives access
to the properties, books and records, contracts, employees, customers,
creditors, landlords, vendors and suppliers of Incubate (the "Organitech Due
Diligence Investigation"). Organitech and Organitech Shareholders will use their
best efforts to complete the Organitech Due Diligence Investigation as promptly
as reasonably practicable.
6.3. Confidentiality . Unless otherwise agreed to in writing by the
parties hereto, each of the parties hereto agrees for itself, its agents and
employees (i) to keep all Proprietary Information (as hereafter defined)
confidential and not to disclose or reveal any Proprietary Information to any
person other than its officers, directors, affiliates, employees, attorneys,
accountants, other agents and representatives who are participating in the
evaluation of the respective company and the transactions contemplated hereby or
who otherwise need to know the Proprietary Information for the purpose of
evaluating the respective company and/or the transactions contemplated hereby;
and (ii) not to use the Proprietary Information for any purpose other than in
connection with the evaluation and/or consummation of the transactions
contemplated hereby.
The obligations under this Section 6.3 shall terminate upon the earlier of (i)
the Closing Date or (ii) one (1) year from the date of termination of this
Agreement. If the Closing is not consummated, each party will, upon the request
of the other party, destroy or return to the disclosing party, as the case may
be, all Proprietary Information which is in writing or can otherwise be
destroyed or returned.
6.4. Notice of Change . Each party covenants and agrees to provide the
other parties with immediate notice of any occurrence which renders any of such
party's (or its Affiliate's) representations and warranties set forth herein
untrue in any material respect.
6.5. Consents, Further Assurances . Consistent with the terms and
conditions hereof, each party hereto will use its best efforts to execute and
deliver such other documents and take such other actions as reasonably requested
by the other party to fulfill the conditions precedent to the obligation of the
other party to consummate the exchange of the Organitech Group Shares and the
Incubate Exchange Shares, or as the other party hereto may reasonably request in
order to carry out this Agreement and the transactions contemplated hereby.
Incubate, Perlstein, Organitech and the Organitech Shareholders shall use their
best efforts and will cooperate with each other to the extent reasonably
necessary to obtain all consents, approvals and waivers, if any, from third
parties required to consummate the transactions contemplated hereby or which, if
not obtained, would materially adversely affect the Condition.
6.6. Compliance With Chief Scientist Office. The parties hereto covenant to
cause Incubate and Organitech to comply, following Closing, with all the rules
and regulations of the Israeli Office of Chief Scientist applicable to Incubate
and/or Organitech.
7. CONDITIONS TO THE OBLIGATION OF INCUBATE
The obligation of Incubate to proceed with the Closing under
this Agreement is subject to the satisfaction, on or prior to the Closing, of
each of the following conditions, each of which may be waived by Incubate:
7.1. Due Diligence. Incubate shall have completed the Incubate Due
Diligence.
7.2. OCS Approval. The Israeli Office of Chief Scientist shall have
approved the transactions contemplated under this Agreement.
7.3. Representations and Warranties True. The representations and
warranties of Organitech and the Organitech Shareholders contained in this
Agreement and the information contained in the Schedules to this Agreement and
any closing documents delivered by Organitech and the Organitech Shareholders in
connection with this Agreement shall have been true and correct in all material
respects when made and shall be true and correct in all material respects at the
Closing Date as though made at such time[, and the Organitech Shareholders (with
respect to themselves) and the President or a Vice President of Organitech (with
respect to Organitech) shall have executed and delivered to Incubate a
certificate to that effect].
7.4. Performance of Obligations . The obligations of Organitech and the
Organitech Shareholders to be performed by any of them on or before the Closing
pursuant to the terms of this Agreement shall have been substantially performed
and complied with in all material respects [and, at the Closing, the Organitech
Shareholders (with respect to themselves) and the President or a Vice President
of Organitech (with respect to Organitech) shall have executed and delivered to
Incubate a certificate to that effect].
7.5. Absence of Litigation . There shall not be any litigation, action or
proceeding pending (including, without limitation, any litigation or proceeding
arising under antitrust or securities laws) to restrain or invalidate the
exchange of the Shares and the Incubate Exchange Shares or the other
transactions contemplated herein.
7.6. Delivery of Specified Documents . Organitech shall have delivered to
Incubate all of the documents and instruments specified in Section 3.2.1 hereof
on or prior to the Closing Date.
7.7. Opinion of Counsel for Organitech . The Organitech Shareholders shall
have delivered to Incubate an opinion of their Israeli counsel, dated the
Closing Date [in the form, scope and substance reasonably satisfactory to
Incubate and containing opinions to the effect that:
7.7.1. Organitech is a corporation duly incorporated, validly existing and
in good standing under the laws of Israel;
7.7.2. Organitech and the Organitech Shareholders have the right, power,
authority and capacity to enter into this Agreement and to perform their
respective obligations under this Agreement, and the Organitech Shareholders
have the right, power, authority and capacity to sell, assign, transfer, convey
and deliver the Organitech Group Shares to Incubate pursuant to this Agreement;
7.7.3. The execution, delivery and performance of this Agreement by
Organitech and the Organitech Shareholders, will not contravene any provision of
Organitech's [Charter documents] and will not result in a breach of, or
constitute a default under, any agreement or other document to which Organitech
or the Organitech Shareholders is a party or by which Organitech or the
Organitech Shareholders are bound and of which such counsel has knowledge, or
any decree, order or rule of any domestic or foreign court or governmental
agency or any provision of applicable law known to such counsel to be binding on
Organitech or the Organitech Shareholders on any of the Organitech Group Shares
or any of Organitech's assets, or result in the creation or imposition of any
mortgage, Lien, assessment, encumbrance, or restriction of any nature on any of
the Organitech Group Shares or any of Organitech's assets or give to others any
interest or rights therein or create in any third party the right to modify,
terminate or accelerate (or to make a claim for damages in respect of) any
instrument or contract to which Organitech or the Organic Shareholders are a
party or by which Organitech or the Organitech Shareholders is bound and of
which such counsel has knowledge;
7.7.4. This Agreement constitutes the valid and binding obligation of
Organitech and the Organitech Shareholders, enforceable against each of them in
accordance with their terms, subject to bankruptcy, reorganization, moratorium,
insolvency or other laws and decisions affecting creditors' rights generally,
public policy considerations and general equity principles. The execution,
delivery and performance of this Agreement has been duly authorized by all
necessary corporate and shareholder action of the Organitech;
7.7.5. No consent by, approval or authorization of or filing, registration
or qualification with any governmental authority is required (i) for the
execution, delivery and performance of this Agreement by the Organitech and the
Organitech Shareholders, (ii) in connection with Organitech and the Organitech
Shareholders'consummation of the transactions contemplated hereby and thereby or
(iii) in order to vest in Incubate good and marketable title in and to all of
the Shares upon the Closing;
7.7.6. The instruments of transfer of the Shares delivered by the
Organitech Shareholders to Incubate at the Closing (i) have been duly authorized
and executed by the Organitech Shareholders, and (ii) assuming the Incubate
Exchange Shares have been issued, delivered and transfered to the Organitech
Shareholders in accordance with this Agreement, are sufficient to convey the
Organitech Shareholders' interest in and to the Organitech Group Shares to
Incubate;
7.7.7. Organitech's authorized capital stock consists of three million
(3,000,000) Ordinary Shares and five hundred thousand (500,000) Preferred Shares
, and to the best knowledge of such counsel, the Organitech Group Shares are the
only shares of capital stock of the Company issued and outstanding except for
the share of capital stock of the Organitech owned by Incubate.
7.7.8. Such counsel has no knowledge, without having undertaken an
independent investigation, of (x) any order, notice, claim, litigation,
proceeding or investigation by or before any court or
governmental agency pending against or directly affecting Organitech or any of
the Organitech Shareholders, or (y) any action or proceeding instituted or
threatened by or before any court or other governmental body to restrain or
prohibit or to obtain damages or other relief in connection with this Agreement
or the transactions contemplated hereby.
8. CONDITIONS TO THE OBLIGATIONS OF ORGANITECH AND THE ORGANITECH
SHAREHOLDERS.
The obligation of Organitech and the Organitech Shareholders
to proceed with the Closing under this Agreement is subject to the satisfaction,
on or prior to the Closing, of each of the following conditions, each of which
may be waived by Organitech and the Organitech Shareholders:
8.1. Due Diligence. Organitech and Organitech Shareholders shall have
completed the Organitech Due Diligence to their satisfaction (including, without
limitation, satisfactory conclusion of its review of Incubate's past activities
including liabilities, taxes, and filing compliance, under any applicable law
including the Security Act). Without limiting the foregoing, Organitech and
Organitech Shareholders shall not be deemed to have concluded a Due Diligence
review as to any matter solely by reason that such matter was, or could have
been, known to either of them as of the execution of this Agreement.
8.2. OCS Approval. The Israeli Office of Chief Scientist shall have
approved the transactions contemplated under this Agreement.
8.3. Tax Ruling. Organitech shall have received a pre-ruling from the
Israeli Tax Commission confirming that (a) the transactions contemplated by this
Agreement shall not be considered as a tax event and (b) Capital Gains Tax shall
apply to the Organitech Shareholders only at the time that any such Organitech
Shareholder sells the Incubate Exchange Shares which he or it will receive under
this Agreement.
8.4. Representations and Warranties True . The representations and
warranties of Incubate and Perlstein contained in this Agreement and the
information in the Schedules to this Agreement and any closing documents
delivered by Incubate in connection with this Agreement shall have been true and
correct in all material respects when made and shall be true and correct in all
material respects at the Closing Date as though made at such time and, at the
Closing, Incubate shall have delivered to Organitech and the Organitech
Shareholders a certificate to that effect signed by its President .
8.5. Performance of Obligations. Each of the
obligations of Incubate to be performed by it on or before the Closing pursuant
to the terms of this Agreement shall have been performed and complied with in
all respects and, at the Closing, Incubate shall have delivered to Organitech
and the Organitech Shareholders a certificate to that effect signed by its
President.
8.6. Absence of Litigation . There shall not be any litigation or
proceeding, pending or threatened (including, without limitation, any litigation
or proceeding arising under antitrust or securities laws), to restrain or
invalidate the exchange of the Organitech Group Shares and the Incubate Exchange
Shares or the other transactions contemplated herein.
8.7. Delivery of Specified Documents . Incubate shall have delivered to
Organitech and the Organitech Shareholders all of the documents and instruments
specified in Section 3.2.2 hereof on or prior to the Closing Date.
8.8. Shareholders Approval . This Agreement and the transactions
contemplated hereby shall have been approved by Perlstein and all Incubate's
shareholders, other than the Incubate Public Shareholders.
8.9. Opinion of Counsel for Incubate . Incubate shall have delivered to the
Organitech Shareholders an opinion of its counsel, _____________________, dated
the Closing Date, to the effect that:
8.9.1. Incubate is a corporation duly incorporated, validly existing and in
good standing under the laws of the State of Colorado (or, in the event of a
Delaware domestication pursuant to Section 8.10 hereof: Incubate is a
corporation duly incorporated, validly existing and in good standing under the
laws of the State of Delaware and a successor by operation of law to Incubate
This! Inc., a Colorado corporation);
8.9.2. Incubate has the right, power, authority and capacity to enter into
this Agreement and to perform its obligations under this Agreement, and has the
right, power, authority and capacity to issue the Incubate Exchange Shares to
the Organitec Shareholders pursuant to this Agreement;
8.9.3. The execution, delivery and performance of this Agreement by
Incubate, will not contravene any provision of Incubates's Articles of
Incorporation and Bylaws and will not result in a breach of, or constitute a
default under, any agreement or other document to which Incubate is a party or
by which Incubate is bound and of which such counsel has knowledge, or any
decree, order or rule of any domestic or foreign court or governmental agency or
any provision of applicable law known to such counsel to be binding on Incubate
or any of its assets, or result in the creation or imposition of any mortgage,
Lien, assessment, encumbrance, or restriction of any nature on any of the
Incubate Exchange Shares or any of Incubate's assets or give to others any
interest or rights therein or create in any third party the right to modify,
terminate or accelerate (or to make a claim for damages in respect of) any
instrument or contract to which Incubate is a party or by which Incuate is bound
and of which such counsel has knowledge;
8.9.4. This Agreement constitutes the valid and binding
obligation of Incubate and Perlstein, enforceable against each of them in
accordance with their terms, subject to bankruptcy, reorganization, moratorium,
insolvency or other laws and decisions affecting creditors' rights generally,
public policy considerations and general equity principles. The execution,
delivery and performance of this Agreement has been duly authorized by all
necessary corporate and shareholder action of the Incubate;
8.9.5. No consent by, approval or authorization of or filing,
registration or qualification with any governmental authority is required (i)
for the execution, delivery and performance of this Agreement by the Incubate,
(ii) in connection with Incubate's consummation of the transactions contemplated
hereby and thereby or (iii) in order to vest in the Organitech Shareholders good
and marketable title in and to all of the Incubate Exchange Shares upon the
Closing;
8.9.6. The issuance of the Incubate Exchange Shares to the
Organitech Shareholders has been duly authorized by the Incubate, and upon such
issuance, the Incubate Exchange Shares will be duly authorized, validly issued,
fully paid, not assessable and free of any liens or rights in other parties;
8.9.7. Incubate's authorized capital stock consists of _____
shares of common stock, ___ value per share, of which _______ shares were issued
and outstanding immediately prior to the Closing, and __________ shares of
Preferred Stock, ____ par value per share, none of which is issued and
outstanding immediately prior to the Closing.
8.9.8. Such counsel has no knowledge, without having
undertaken an independent investigation, of (x) any order, notice, claim,
litigation, proceeding or investigation by or before any court or governmental
agency pending against or directly affecting Incubate, or (y) any action or
proceeding instituted or threatened by or before any court or other governmental
body to restrain or prohibit or to obtain damages or other relief in connection
with this Agreement or the transactions contemplated hereby.
8.10. Delaware Domestication. Unless waived in writing by the Organitech
Shareholders, Incubate shall have transferred its domestication to Delaware
prior to Closing, to the end that at Closing, Incubate shall be a validly
existing Delaware corporation; and all of the representations, warranties and
covenants of Incubate set forth
herein shall be deemed modified to the limited extent necessary to reflect its
Delaware (rather than Colorado) jurisdiction of incorporation.
8.11. Incubate's bylaws shall provide that any (i) public offering or
private placement of Incubate's securities(other than the issuance of securities
to a [strategic investor] not involving the dissemination of a private placement
memorandum to multiple offerees), (ii) appointment or removal of its CEO, (iii)
appointment or removal of its CFO, and (iv) granting of any registration rights
to any shareholder, shall require the prior consent of no less than 75% of the
voting power of Incubate's capital stock, and that any change in such provision
shall require a similar 75% shareholder consent.
8.12. The designees of the Organitech Shareholders to Incubate's board
of directors listed on Schedule 3.2.2.3 shall have been duly elected to
Incubate's board of directors prior to Closing. It is agreed by the parties that
prior to May of 2001 any change in the designees, including their removal from
the board of directors, shall require the consent of no less than 75% of the
voting power of Incubate's capital stock.
8.13. It is agreed by the parties that Arie Heller shall be appointed
as a non-voting observer to Incubate's board of directors prior to Closing and
shall remain in said position until October 2001.
8.14 The parties agree to set up a search committee for a CEO. The
search committee will work to identify a candidate for the CEO. The search
committee is expected to recommend a candidate within 3 months. If it is
successful in identifying a candidate for the position of CEO, it will recommend
him to the shareholders and his appointment shall be approved as set forth in
Section 8.11 above. The search committee shall consist of Sharone Perlstein,
Zohar Gendler, Arie Heller and Lior Hessel.
8.15 Organitech's budget for the year 2000 shall continue according to
the currently approved budget plus expenses associated with the transactions
contemplated herein. Following the Closing, the General Manager (Lior Hessel) or
his replacement will submit to the board of directors of Incubate a budget for
the year 2001 based on the funds referred to in Section 5.3.4 above.
9. INDEMNIFICATION
9.1. General
9.1.1. Organitech hereby agrees to indemnify, defend and hold
harmless Incubate from and against any and all Losses arising out of, based upon
or resulting from (i) any false representation or warranty of Organitech which
is contained in or made pursuant to this Agreement; (ii) any breach by
Organitech of any of their agreements or obligations contained in or made
pursuant to this Agreement; and (iv) any and all Legal Expenses arising out of
the foregoing. To avoid doubt, the Losses shall be limited to the amount
required for the curing of any breach.
9.1.2. TEIC hereby agrees to indemnify, defend and hold
harmless Incubate for any direct Losses occurring from false representations
contained in Sections 4.1, 4.2, 4.9, 4.10, 4.11, 4.25 and 4.34.
9.1.3. Hessel hereby agrees to indemnify, defend and hold
harmless Incubate for any direct Losses occurring from false representations
contained in Sections 4.1, 4.2, 4.3 (as to himself only), 4.4 (as to himself
only), 4.5, 4.6 (as to himself only), 4.7, 4.8 (as to himself only), 4.9, 4.10
(as to himself only), 4.11, 4.17,
4.20.2, 4.20.3, 4.38 (as to himself only) and 4.41 (as to himself only. To avoid
doubt, the indemnification obligations of Hessel vis a vis the representations
of the Organitech Shareholders apply to himself only and not to any other
shareholder.
9.1.4. Incubate and Perlstein hereby agree to indemnify,
defend and hold harmless the Organitech Shareholders from and against any and
all Losses arising out of, based upon or resulting from (i) any false
representation or warranty of Incubate which is contained in or made pursuant to
this Agreement, (ii) any breach of Incubate prior to Closing of any of its
agreements or obligations contained in or made pursuant to this Agreement; and
(iii) any and all Legal Expenses arising out of the foregoing.
9.2. Procedure. Promptly after receipt by any person entitled to
indemnification under this Section 9 (an "Indemnified Party") of notice of the
commencement of any action in respect of which the indemnified party will seek
indemnification hereunder, the indemnified party shall so notify in writing the
person(s) from whom indemnification hereunder is sought (collectively, the
"Indemnifying Party"), but any failure so to notify the indemnifying party shall
not relieve it from any liability that it may have to the indemnified party
under this Section 9 except to the extent that the indemnifying party's ability
to defend such claim is materially prejudiced by the failure to give such
notice. The indemnifying party shall be entitled to participate in the defense
of such action and to assume control of such defense; provided, however, that:
9.2.1. the indemnified party shall be entitled to participate
in the defense of such claim and to employ counsel at its own expense to assist
in the handling of such claim;
9.2.2. the indemnifying party shall obtain the prior written
approval of the indemnified party before entering into any settlement of such
claim or ceasing to defend against such claim, if, pursuant to or as a result of
such settlement or cessation, injunctive or other equitable relief would be
imposed against the indemnified party;
9.2.3. the indemnifying party shall not consent to the entry
of any judgment or enter into any settlement that does not include as an
unconditional term thereof the giving by the claimant or plaintiff to each
indemnified party of a release from liability in respect of such claim; and;
9.2.4. the indemnifying party shall not be entitled to control
but shall be entitled to participate at its own expense in the defense of, and
the indemnified party shall be entitled to have sole control at its own expense
over, the defense or settlement of any claim to the extent the claim seeks an
order, injunction or other equitable relief against the indemnified party which,
if successful, could materially interfere with the business, operations, assets,
condition or prospects of the indemnified party.
9.3. Reimbursement. After written notice by the indemnifying party to
the indemnified party of its election to assume control of the defense of any
such action, the indemnifying party shall not be liable to such indemnified
party hereunder for any Legal Expenses subsequently incurred by such indemnified
party in connection with the defense thereof. If the indemnifying party does not
assume control of the defense of such claims as provided in this Section 9, the
indemnified party shall have the right to defend such claim in such manner as it
may deem appropriate at the cost and expense of the indemnifying party, and the
indemnifying party will promptly reimburse the indemnified party therefor in
accordance with this Section. The reimbursement of fees, costs and expenses
required by this Section 9 shall be made by periodic payments during the course
of the investigation or defense, as and when bills are received or expenses
incurred.
9.4. Survival . The representations and warranties, agreements, and
indemnifications of the parties contained in this Agreement or in any writing
delivered pursuant to the provisions of this Agreement shall survive the date of
the Closing and shall continue in full force and effect for a [twenty four (24)
month] (the "Survival Period") following the Closing Date, and thereafter shall
terminate and be of no further force or effect, except with respect to (i)
liabilities for any item as to which, prior to the end of the Survival Period,
the Organitech Shareholders or Incubate, as the case may be, shall have asserted
a claim in writing as required pursuant to the provisions of this Section 9,
which claim shall identify the basis with reasonable specificity, and (ii)
any Tax or securities liability, which liability for such claim shall continue
until it shall have been finally settled, decided or adjudicated.
9.5. Limitation
9.5.1. Other than the Indemnification provided for herein none
of the indemnifying parties are responsible for any additional compensation and
in no event shall there be any indemnification for the first aggregate amount of
one hundred thousand dollars (100,000) for each indemnifying party for each
indemnifiable event.
9.5.2. The indemnification of Organitech, TEIC and Hessel
shall be limited to an aggregate amount of their pro rata share of three million
dollars based on their holdings.
9.5.3. The indemnification of Incubate and Perlstein shall be
limited to an aggregate amount of up to US$ 3 Million. The indemnification
obligations expressly set forth in this Section 9, shall constitute the
exclusive remedy against the Organitech Shareholders for any claim whatsoever
under this Agreement by any of Perlstein, Incubate, its shareholders, directors,
officers and their successors. However, nothing set forth herein shall be deemed
to confer any benefit under this Agreement on any third party, which benefits
are hereby expressly denied.
9.6 Indemnification Procedure. In the event of an indemnifiable event
Hessel and TEIC shall have the option at their sole discretion to elect to
indemnify via cash or to give back shares (or a combination of cash and shares)
to Incubate based on a valuation of $1 per each Incubate Exchange Share (as
adjusted from time to time on account of split, combination, stock dividend
etc.).
10. TERMINATION
10.1. Termination . This Agreement may be terminated prior to the Closing
as follows:
10.1.1. at the election of Incubate, if any one or more of the conditions
to its obligation to proceed with the Closing, set forth in Section 7, has not
been fulfilled on the Closing Date;
10.1.2. at the election of the Organitech Shareholders or Organitech, if
any one or more of the conditions to their obligation to proceed with the
Closing set forth in Section 8, has not been fulfilled on the Closing Date;
10.1.3. at the election of Incubate, if Organitech Shareholders or
Organitech has breached any representation, warranty, covenant or agreement
contained in this Agreement, which breach cannot be or is not cured by the
Closing Date;
10.1.4. at the election of the Organitech Shareholders or Organitech, if
Incubate has breached any representation, warranty, covenant or agreement
contained in this Agreement, which breach cannot be or is not cured by the
Closing Date;
10.1.5. at the election of Incubate, the Organitech
Shareholders or Organitech, if any legal proceeding is commenced or threatened
by any governmental or regulatory body or other person (other than Incubate, the
Organitech Shareholders or Organitech) directed against the consummation of the
Closing and either Incubate, the Organitech Shareholders or Organitech, as the
case may be, reasonably and in good faith deems it impractical or inadvisable to
proceed in view of such legal proceeding or threat thereof, taking into account
the potential expense and delay likely to be involved; or
10.1.6. at any time on or prior to the Closing Date, by mutual written
consent of Incubate, the Organitech Shareholders and Organitech.
10.2. If this Agreement so terminates, it shall become null and void
and have no further force and effect, except as provided in Section 10.3.
10.3. Survival . If this Agreement is validly terminated pursuant to
Section 10.1 and the transactions contemplated hereby are not consummated as
described above, this Agreement shall become void and of no further force and
effect; provided, however, that if Incubate terminates this Agreement because
any of the conditions contained in Section 7.3 or Section 7.4 have not been
satisfied, or if the Organitech Shareholders or Organitech terminates this
Agreement because any of the conditions contained in Section 8.4 or Section 8.5
have not been satisfied then the terminating party shall have the right to
pursue all of its legal remedies for breach of contract and damages; provided
further that if this Agreement is validly terminated pursuant to Section 10.1
and the transactions contemplated hereby are not consummated as described above,
the provisions of Section 6.3 relating to the obligation of to keep confidential
and not to use certain information and to return documents and copies thereof to
the disclosing party, and the provisions of Section 10.3 relating to
responsibility for expenses shall survive. No party hereto shall have any
liability to any other party in respect of a valid termination of this Agreement
pursuant to Section 10.1, except to the extent set forth above.
10.4. Expenses if No Closing . If the Closing does not occur and the
transactions contemplated hereby are not consummated, then, subject to the right
of a non-defaulting party to recover damages, costs and expenses from a
defaulting party pursuant to Section 10.3, all costs and expenses incurred in
connection with this Agreement shall be paid by the group incurring such
expenses, i.e., by Incubate if incurred by Incubate, by the Organitech if
incurred by the Organitech Shareholders or Organitech.
11. GENERAL.
11.1. No Tax Representations . The Organitech Shareholders, Organitech and
Incubate agree that no representation or warranty has been made by them as to
the tax consequences of the transactions contemplated by this Agreement, that
each is engaging separate counsel with respect to such tax consequences, and
that each is assuming its own respective tax liability, if any, arising out of
this Agreement or the consummation of the transactions contemplated hereunder.
11.2. Knowledge Qualification. Whenever a representation or warranty is
made herein based on the knowledge of Incubate or Organitech (as the case may
be) such knowledge shall be deemed to refer to the actual knowledge of the Chief
Executive Officer, the President or any Vice President of Incubate or Organitech
(as the case may be).
11.3. Binding Effect and Assignment . This Agreement shall be binding upon
and inure to the benefit of and be enforceable by each of the parties and their
respective successors and assigns. This Agreement may not be assigned by either
party without the prior written consent of the other party.
11.4. Waiver . Any term or provision of this Agreement may be waived at
any time by the party entitled to the benefit thereof by a written instrument
duly executed by such party.
11.5. Notices . All notices, requests, demands, waivers, consents,
approvals, or other communications which are required or permitted hereunder
shall be in writing and shall be delivered personally, sent by reputable
overnight courier service (such as Federal Express), sent by telecopier, or sent
by registered or certified mail, return receipt requested, postage prepaid, to
the addresses set forth below:
If to Organitech Shareholders or Organitech (prior to Closing):
Organitech Ltd
P.O.B. 212
Nesher 36601, Israel
Telecopier No. ___________________
Attention: Lior Hessel
With a copy to:
Avi Goldsobel, Adv.
Matam-Advanced Technology Center
Building No. 30
Haifa
Telecopier No. ___________________
Attention: Avi Goldsobel, Adv.
and
[Benjamin Strauss, Esquire
Pepper Hamilton LLP
Suite 1600
1201 Market Street
Wilmington, Delaware 19801
Telecopier No.302-656-8865]
If to Incubate (or Organitech after Closing):
Incubate This! Inc.
265 Sunrise Avenue, Suite 204
Palm Beach, Florida 33480
Telecopier No. ___________________
Attention:________________________
\ With a copy to:
Mintmire & Associates
265 Sunrise Avenue, Suite 204
Palm Beach, Florida 33480
Telecopier No. ____________________
Attention: ________________________
or to such other address or telecopier number as the party entitled to receive
such notice may, from time to time, specify in writing to the other party.
11.6. Governing Law . This Agreement shall be governed as to its validity,
interpretation and effect by the laws of the State of New York.
11.7. No Third_Party Beneficiaries . Notwithstanding anything to the
contrary contained herein, no provision of this Agreement is intended to benefit
any person other than the signatories hereto nor shall any such provision be
enforceable by any other person.
11.8. Severability . Any provision of this Agreement which is invalid or
unenforceable in any jurisdiction shall be ineffective to the extent of such
invalidity or unenforceability without invalidating or rendering unenforceable
the remaining provisions hereof, and any such invalidity or unenforceability in
any jurisdiction shall not invalidate or render unenforceable such provision in
any other jurisdiction.
11.9. Schedules . All Schedules referred to in this Agreement are intended
to be and are specifically incorporated by reference herein.
11.10. Public Announcements . Neither the Organitech Shareholders,
Organitech nor Incubate, without the prior written consent of the others, will
make any press release or other similar public announcement concerning the
transactions contemplated hereby, except as mandated (in the disclosing party's
reasonable discretion) by applicable securities rules and regulations; provided,
however, that at such time that a party hereto desires to publicize or otherwise
release information relating to the subject matter hereof, Incubate and
Organitech shall mutually agree upon the content and the method of release of
such publicity or other release.
11.11. Section Headings . All section headings herein have been inserted
for convenience of reference only and shall in no way modify or restrict any of
the terms or provisions hereof.
11.12. Contents of Agreement . This Agreement sets forth the entire
understanding of the parties hereto with respect to the transaction contemplated
hereby and shall not be amended or terminated except by a written instrument
duly executed by each of the parties hereto. Any and all prior or
contemporaneous agreements or understandings between or among the parties
regarding the subject matter hereof[, including without limitation, the
Memorandum of Understanding for the Exchange of Common Stock dated September __,
2000 between Organitech and Incubate] are superseded in their entirety by this
Agreement.
11.13. Counterparts . This Agreement may be executed in two or more fully
executed counterparts, including by facsimile, each of which shall be deemed an
original, but all of such counterparts together shall constitute but one and the
same instrument.
[signatures on the following page]
IN WITNESS WHEREOF, the parties have executed this Stock
Exchange Agreement on the date first written above.
/s/ Lior Hessel
Lior Hessel Incubate This! Inc.
By:/s/ Sharone Perlstein
Technion Entrepreneurial Incubator Company Ltd. _________________________
By:__________________________
- -----------------------
D. G. Pizza Ltd.
By:___________________
/s/ Arie Heller
Arie Heller
/s/Anat Heller
Anat Heller
Organitech Ltd.
By:__________________